The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS)
- PMID: 29204893
- PMCID: PMC5825318
- DOI: 10.1007/s13555-017-0213-2
The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS)
Abstract
Introduction: Patient-reported outcome measures (PROs) specific for genital psoriasis (GenPs) have not been described.
Methods: In this cross-sectional, qualitative study in patients with moderate-to-severe GenPs, we sought to develop a PRO useful for GenPs symptom assessment. A literature review was performed to identify relevant psoriasis or GenPs symptoms and existing PROs that may be useful in the evaluation of symptom severity in GenPs patients. The literature review findings were discussed with clinicians, and then patients with GenPs.
Results: Relevant psoriasis or GenPs symptoms from the literature review included itch, pain, scaling, redness/erythema, and stinging/burning. The validity of these symptoms for GenPs and potentially relevant PROs was corroborated by clinical experts. After gap analysis, a draft symptom scale consisting of Numeric Rating Scale (NRS) items was constructed. We then conducted interviews with GenPs patients (n = 20) to support content validity and use of the draft symptom NRS items in routine practice and in clinical trials. Participants identified and confirmed relevant symptoms and evaluated the utility of the draft PRO. A new PRO was developed: the Genital Psoriasis Symptoms Scale (GPSS). Cognitive debriefing and cultural adaptation/translation interviews with a second group of patients confirmed cultural appropriateness of the GPSS.
Conclusion: The GPSS may be useful for assessing symptoms before, during, and after treatment in routine clinical practice and in clinical trials involving patients with GenPs.
Funding: Eli Lilly & Company. Plain language summary available for this article.
Keywords: Genital psoriasis; Health-related quality of life; Patient-reported outcomes; Psoriasis.
Similar articles
-
The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health.Dermatol Ther (Heidelb). 2018 Mar;8(1):33-44. doi: 10.1007/s13555-017-0212-3. Epub 2017 Dec 4. Dermatol Ther (Heidelb). 2018. PMID: 29204894 Free PMC article.
-
Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study.J Sex Med. 2018 Nov;15(11):1645-1652. doi: 10.1016/j.jsxm.2018.09.004. J Sex Med. 2018. PMID: 30415816 Clinical Trial.
-
Patients' Perspectives on the Impact of Genital Psoriasis: A Qualitative Study.Dermatol Ther (Heidelb). 2017 Dec;7(4):447-461. doi: 10.1007/s13555-017-0204-3. Epub 2017 Oct 26. Dermatol Ther (Heidelb). 2017. PMID: 29076000 Free PMC article.
-
Prevalence of genital psoriasis in patients with psoriasis.J Dermatolog Treat. 2018 Dec;29(8):754-760. doi: 10.1080/09546634.2018.1453125. Epub 2018 Mar 28. J Dermatolog Treat. 2018. PMID: 29565190 Review.
-
Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS).Curr Med Res Opin. 2019 Jul;35(7):1139-1148. doi: 10.1080/03007995.2018.1560222. Epub 2019 Jan 17. Curr Med Res Opin. 2019. PMID: 30561230 Review.
Cited by
-
Distribution of monetary incentives in health insurance scheme influences acupuncture treatment choices: An experimental study.PLoS One. 2019 Jun 10;14(6):e0218154. doi: 10.1371/journal.pone.0218154. eCollection 2019. PLoS One. 2019. PMID: 31181131 Free PMC article.
-
Updates on Psoriasis in Special Areas.J Clin Med. 2024 Dec 11;13(24):7549. doi: 10.3390/jcm13247549. J Clin Med. 2024. PMID: 39768472 Free PMC article. Review.
-
Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial.Acta Derm Venereol. 2020 Jan 7;100(1):adv00006. doi: 10.2340/00015555-3353. Acta Derm Venereol. 2020. PMID: 31620802 Free PMC article. Clinical Trial.
-
A Common Genetic Background for Psoriasis and Cardiovascular Diseases: A Narrative Review.Health Sci Rep. 2025 Aug 13;8(8):e71128. doi: 10.1002/hsr2.71128. eCollection 2025 Aug. Health Sci Rep. 2025. PMID: 40809699 Free PMC article.
-
Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis.J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1257-1262. doi: 10.1111/jdv.16181. Epub 2020 Feb 5. J Eur Acad Dermatol Venereol. 2020. PMID: 31919919 Free PMC article. Clinical Trial.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous